Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s): LBLTF

Healthcare Biotechnology

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.

TSXV:LBL.H - Post by User

Lattice Biologics Ltd

Bullboard Posts

Comment by Actuarialon Jan 04, 2017 9:36am

165 Views

Post# 25665113

RE:RE:RE:RE:Great progress in 2016!!

Thanks Laroplex. I would be more optimistic about LBL s/p in long term. A comparable company Anika therapeutics market cap $732M revenue $105M PE ratio 21.50. LBL has a much better product AmnioVisc though it takes time to steal market share from Anika. Assume LBL reach $36M revenue target by 2019, then its market cap should be around $250M = $732/$105 * $36 => $3.5 S/P, or, EPS = 0.123 = ($36 * 35% - $4) / 70 => $2.5 S/P. Therefore, I would not be surprised to see LBL s/p be around $3 soon. In addition, LBL is ahead of planned growth; LBL is going to release more new products; LBL BioGel has hugh potential in the hugh personal med market. $10 per share is not going to be an unrealistic guess. GLTA

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?